ReviewCancer cell international2025
Overcoming CAR-T bottlenecks in high-risk DLBCL: a molecular subtyping enhancement strategy.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.British journal of haematology · 2026Article
- Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and exhibits significant molecular heterogeneity, leading to varied treatment responses among patients. Although Chimeric Antigen Receptor T-cell therapy (CAR-T) has made remarkable progress in relapsed/refractory (R/R) DLBCL, particularly in patients resistant to standard treatments, the therapeutic efficacy of CAR-T therapy remains inconsistent for high-risk subtypes, such as double-hit/triple-hit lymphoma (DHL/THL) and TP53 mutations. This paper focuses on the molecular subtyping of DLBCL and its application in CAR-T therapy. By analyzing factors such as metabolic stress, immune evasion, and epigenetic regulation, this study reveals how these mechanisms influence the function and efficacy of CAR-T cells. Furthermore, it discusses strategies for overcoming treatment challenges in high-risk subtypes through molecular profiling, metabolic modulation, epigenetic interventions, and multi-target combination therapies. The paper also explores future research directions in CAR-T cell engineering and immune evasion mechanisms. This research provides a novel theoretical framework for personalized treatment and offers valuable insights for clinical treatment strategies for high-risk DLBCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.